The Lancet Haematology· Nichola Cooper, David J Kuter, Henrik Frederiksen, Bing Han, Frederick Chen, Wilma Barcellini, Bruno Fattizzo, Joan Cid, Catherine M Broome, Miriam Vara Pampliega, Amitabha Mazumder, Alessandro Lucchesi, Xin Zhao, Antonio Risitano, Sumit Sawhney, Quentin A Hill, Deepthi Jayawardene, Heidi Krenz, Lei Wang, Jing Zhao, Ahmed Daak·· 2026-10-01AI 评分49
LUMINA 2 II期单臂研究:口服BTK抑制剂rilzabrutinib在温抗体型自身免疫性溶血性贫血中显示血红蛋白应答
[Articles] Rilzabrutinib, an oral Bruton tyrosine kinase inhibitor, in patients with warm autoimmune haemolytic anaemia: a prospective, single-arm, multicentre, phase 2b safety and clinical activity study (LUMINA 2)
AI 导读
LUMINA 2 是一项前瞻性、单臂、多中心 IIb 期研究,口服 BTK 抑制剂 rilzabrutinib 在经治温抗体型自身免疫性溶血性贫血患者中显示总体且持久的血红蛋白应答,研究者报告安全性良好。作者认为该药可能通过多免疫调节作用于疾病本身的病理生理,并有机会减少或停用糖皮质激素。研究为单臂设计,未设对照组。
来源:The Lancet Haematology · thelancet.com